RHINOLAST

This brand name is authorized in Ireland, Israel, Malta, New Zealand, United Kingdom, South Africa

Active ingredients

The drug RHINOLAST contains one active pharmaceutical ingredient (API):

1 Azelastine UNII 0L591QR10I - AZELASTINE HYDROCHLORIDE

Azelastine, a phthalazinone derivative is classified as a potent long-acting anti-allergic compound with selective H1 antagonist properties. An additional anti-inflammatory effect could be detected after topical ocular administration. Data from in vivo (pre-clinical) and in vitro studies show that azelastine inhibits the synthesis or release of the chemical mediators known to be involved in early and late stage allergic reactions e.g. leukotriene, histamine, PAF and serotonin. Read about Azelastine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RHINOLAST Nasal spray	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R01AC03	Azelastine	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AC Antiallergic agents, excl. corticosteroids
Discover more medicines within R01AC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 146529, 180665, 73863
Country: IE	Health Products Regulatory Authority	Identifier(s): 44204
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4557
Country: MT	Medicines Authority	Identifier(s): AA1187/03501
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7489
Country: ZA	Health Products Regulatory Authority	Identifier(s): 27/5.7.1/0590